Earnings History Data for Amylyx Pharmaceuticals, Inc. (AMLX) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It focuses on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc. is based in CAMBRIDGE, Mass.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22-02-2024 | PM | AMLX | Amylyx Pharmaceuticals, Inc. | 1,070 | 0.07 | 0.20 | -0.65 | Amylyx Pharmaceuticals GAAP EPS of $0.07 misses by $0.16, revenue of $108.4M beats by $1.36M [2/22/2024 7:03 AM] |
18.46 | 3.15 (20.61%) |
16.62 | 1.31 (8.56%) |
11.82 - 38.32 | 5,100,760 | 970,000 | 204,617 | ||
| 09-11-2023 | PM | AMLX | Amylyx Pharmaceuticals, Inc. | 1,230 | 0.30 | 0.42 | -0.92 | Amylyx Pharmaceuticals GAAP EPS of $0.30 misses by $0.12, revenue of $102.7M misses by $10.96M [11/9/2023 7:38 AM] |
12.31 | -5.69 (-31.58%) |
12.62 | -5.38 (-29.89%) |
12.24 - 41.93 | 9,348,814 | 1,340,000 | 543,070 | ||
| 10-08-2023 | AH | AMLX | Amylyx Pharmaceuticals, Inc. | 1,460 | 0.31 | 0.01 | -0.93 | Amylyx Pharmaceuticals GAAP EPS of $0.31 beats by $0.35, revenue of $98.2M beats by $6.06M [8/10/2023 4:30 PM] |
21.63 | 0.46 (2.17%) |
21.20 | 0.03 (0.14%) |
15.80 - 41.93 | 1,700,051 | 1,110,000 | 5,154 | ||
| 11-05-2023 | AH | 4:00 PM ET (May 11) |
AMLX | Amylyx Pharmaceuticals, Inc. | 2,010 | 0.02 | -0.27 | -0.93 | Amylyx Pharmaceuticals GAAP EPS of $0.02 beats by $0.24, revenue of $0.07M misses by $59.58M [5/11/2023 4:06 PM] |
27.67 | -1.15 (-3.99%) |
30.50 | 1.68 (5.83%) |
6.51 - 41.93 | 2,850,096 | 750,000 | 73,658 | |
| 13-03-2023 | AH | 4:00 PM ET (Mar 13) |
AMLX | Amylyx Pharmaceuticals, Inc. | 2,400 | -0.65 | -0.77 | 0.00 | Amylyx Pharmaceuticals GAAP EPS of -$0.65 beats by $0.16, revenue of $21.89M beats by $17.17M [3/13/2023 4:27 PM] |
34.21 | 3.04 (9.75%) |
37.23 | 6.06 (19.44%) |
6.51 - 41.93 | 3,768,472 | 780,000 | 84,457 | |
|
||||||||||||||||||
| 10-11-2022 | AH | 4:00 PM ET (Nov 10) |
AMLX | Amylyx Pharmaceuticals, Inc. | 2,010 | -0.92 | -0.97 | 0.00 | Amylyx Pharmaceuticals GAAP EPS of -$0.92 beats by $0.04, revenue of $0.35M beats by $0.27M [11/10/2022 4:15 PM] |
34.10 | -1.29 (-3.63%) |
34.25 | -1.14 (-3.22%) |
6.51 - 38.76 | 1,237,848 | 790,000 | 6,663 | |
| 12-05-2022 | AH | AMLX | Amylyx Pharmaceuticals, Inc. | 446.00 | -0.93 | -0.75 | 0.00 | Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.19 [5/12/2022 5:11 PM] |
8.56 | 1.08 (14.44%) |
7.93 | 0.45 (6.02%) |
6.51 - 33.41 | 105,267 | 270,000 | 207 | ||